|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||1.5180 - 1.6700|
|52 Week Range||1.4120 - 3.4450|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.63|
If you own shares in Mauna Kea Technologies SA (EPA:MKEA) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers...
Mauna Kea Technologies (MKEA.PA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of the Cellvizio AQ-Flex™ 19 Confocal Miniprobe™ through existing bronchoscopes, transbronchial needles and other bronchoscopic accessories. “Our pioneering team has demonstrated that real-time imaging and identification of benign and malignant cellular structures inside pulmonary nodules and lymph nodes with needle-based Confocal Laser Endomicroscopy is not only feasible but highly reproducible.” said Pr. The Cellvizio AQ-Flex™ 19 Confocal Miniprobe™ can be used through the working channel of existing navigation products to provide direct “through the needle” visualization inside peripheral lesions.
Mauna Kea Technologies (MKEA.PA) (MKEAF) (MKEA.NX) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced a mutual decision to terminate the development and distribution agreements with Cook Medical. “Mauna Kea announced a change in commercial strategy in the Fall of 2015 which included moving to an expanded marketing system to commercialize Cellvizio in new clinical applications through strategic sales partnerships with established medical device companies,” said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. “In December 2015, the Company signed the first of these strategic partnerships when it announced a multi-year worldwide exclusive marketing partnership agreement with Cook Medical to use the Cellvizio platform in urological applications.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Mauna Kea Technologies SARead More...
Two important questions to ask before you buy Mauna Kea Technologies SA (EPA:MKEA) is, how it makes money and how it spends its cash. What is left after investment, determines Read More...
While small-cap stocks, such as Mauna Kea Technologies SA (EPA:MKEA) with its market cap of €73m, are popular for their explosive growth, investors should also be aware of their balance Read More...
Mauna Kea Technologies (MKEA.PA) (MKEAF) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced results from the large, prospective, multi-center validation CONTACT 2 study that met its primary and secondary endpoints, demonstrating significantly higher diagnostic performance of nCLE with Cellvizio® compared to standard of care methods in patients with pancreatic cyst lesions (PCLs). The findings were published in the article “Needle-based confocal laser endomicroscopy of pancreatic cystic lesions: a prospective multicenter validation study in patients with definite diagnosis” in the peer-reviewed publication Endoscopy.
If you own shares in Mauna Kea Technologies SA (EPA:MKEA) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a Read More...
Results of breakthrough PERSEE trial involving live transmission and robotized use of Cellvizio confocal miniprobe published online in Surgical Endoscopy
Mauna Kea Technologies (MKEA.PA) (MKEAF) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced a new peer-reviewed publication in Surgical Endoscopy highlighting positive results of utilizing Cellvizio to aid in the screening and surveillance of Barrett’s Esophagus. The article, entitled “Real-time diagnosis of Barrett’s esophagus: a prospective, multicenter study comparing confocal laser endomicroscopy with conventional histology for the identification of intestinal metaplasia in new users,” reports considerably more sensitive results when using pCLE in detecting Barrett’s Esophagus than the Seattle Protocol, which is part of the current theoretical diagnostic standard.
PARIS-- -- The availability of the needle-based Cellvizio platform, now bearing CE mark, could be a game changer for the management of patients with certain pulmonary diseases including lung cancer. Ground-breaking work from the interventional pulmonology team at the Amsterdam Academic Medical Center will be highlighted among five other presentation sessions during ERS, the largest meeting of respiratory ...
Every investor in Mauna Kea Technologies SA (EPA:MKEA) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insidersRead More...
Investors are always looking for growth in small-cap stocks like Mauna Kea Technologies SA (EPA:MKEA), with a market cap of €75.42m. However, an important fact which most ignore is: howRead More...
Mauna Kea Technologies (MKEA.PA) (MKEAF) (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary probe-based confocal laser endomicroscopy (pCLE) platform, today announced the publication of a prospective multicenter study (ClinicalTrials.gov Identifier: NCT01033201) that demonstrates the potential of Cellvizio to aid in the diagnosis of acute cellular rejection in lung transplant patients. The article, entitled “Diagnosis of Acute Cellular Rejection Using Probe-Based Confocal Laser Endomicroscopy in Lung Transplant Recipients: a Prospective, Multi-Center Trial,” was published in Transplantation (2018, DOI: 10.1097/TP.0000000000002306) and can be downloaded here: https://journals.lww.com/transplantjournal/Abstract/onlinefirst/Diagnosis_of_Acute_Cellular_Rejection_Using.96508.aspx.
Mauna Kea Technologies (MKEA.PA) (MKEAF) (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the Cellvizio® 100 series F400 and F800 with a new Confocal Miniprobe™, the CranioFlex™, to be used during neurosurgical procedures. This marks the 15th U.S. FDA 510(k) clearance of Cellvizio® and the first-ever FDA clearance for CLE applications in neurosurgery. The Cellvizio® 100 with the CranioFlex™ provides imaging of tissue internal microstructures and allows the identification of cells and vessels and their organization within the central nervous system during cranial diagnostic and therapeutic procedures such as tumor biopsy and resection.